Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Ask a Doctor is new series of physician-authored columns offering insights and advice on common health topics. It is not a ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus ®, which has been accepted for review by the European Medicines Agency (EMA) and the US ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

A MOTHER has revealed that she lost over eight stone after using fat jabs for two years. Bridget claimed that everyone said ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to ...